Clinically, the humanized therapeutic sclerostin antibody (romosozumab) demonstrated the bone anabolic potential against postmenopausal osteoporosis, whereas imposed severe cardiac ischemic events (BRIDGE and ARCH) 5-8. Here, SOST is linked to postmenopausal osteoporosis.